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Ecto-5’-nucleotidase (e5NT) belongs to the family of
metallophosphoesterases, hydrolyses AMP to adenosine,
and is a regulator of the adenosine signaling pathway
[1]. It has been shown, that free adenosine is involved in
various diseases and cancer progression [2,3]. In a pre-
vious study, a molecular model of e5NT has been cre-
ated and used for the identification of new sulfonamide
inhibitors [4]. Recently, X-ray structures of human
e5NT in complex with different inhibitors were pub-
lished [5]. This made it possible to reevaluate the model
building and virtual screening efforts in detail. An
extensive analysis of the comparative e5NT model, built
using a bacterial enzyme in the presence of 35%
sequence identity as a template, showed that the model
was topologically correct and had high accuracy within
the active site region. Comparative docking studies were
carried out to explore inhibitor binding characteristics
within the X-ray structure and the model. The results
provided plausible explanations for the successful identi-
fication of new e5NT inhibitors by model-based virtual
screening and highlighted important parameters [6].
Published: 11 March 2014
References
1. Zimmermann H, Zebisch M, Sträter N: Cellular function and molecular
structure of ecto-nucleotidases. Purinergic Signalling 2012, 8:437-502.
2. Deaglio S, Robson SC: Ectonucleotidases as regulators of purinergic
signalling in thrombosis, inflammation, and immunity. Adv Pharmacol
2011, 61:301-332.
3. Zhang B: CD73: a novel target for cancer immunotherapy. Cancer Res
2010, 70:6407-6411.
4. Ripphausen P, Freundlieb M, Brunschweiger A, Zimmermann H, Müller CE,
Bajorath J: Virtual screening identifies novel sulfonamide inhibitors of
ecto-5‘-nucleotidase. J Med Chem 2012, 55:6576-6581.
5. Knapp K, Zebisch M, Pippel J, El-Tayeb A, Müller CE, Sträter N: Crystal
structure of the human ecto-5’-nucleotidase (CD73): insights into the
regulation of purinergic signaling. Structure 2012, 20:2161-2173.
6. Furtmann N, Bajorath J: Evaluation of molecular model-based discovery
of ecto-5’-nucleotidase inhibitors on the basis of X-ray structures. Bioorg
Med Chem .
doi:10.1186/1758-2946-6-S1-P13
Cite this article as: Furtmann and Bajorath: Evaluation of molecular
model-based discovery of ecto-5’-nucleotidase inhibitors on the basis of
X-ray structures. Journal of Cheminformatics 2014 6(Suppl 1):P13.
Open access provides opportunities to our 
colleagues in other parts of the globe, by allowing 
anyone to view the content free of charge.
Publish with ChemistryCentral and every
scientist can read your work free of charge
W. Jeffery Hurst, The Hershey Company.
available free of charge to the entire scientific community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central
yours     you keep the copyright
Submit your manuscript here:
http://www.chemistrycentral.com/manuscript/
Department of Life Science Informatics, B-IT, LIMES Program Unit Chemical
Biology and Medicinal Chemistry, Rheinische Friedrich-Wilhelms-Universität,
Dahlmannstrasse 2, D-53113 Bonn, Germany
Furtmann and Bajorath Journal of Cheminformatics 2014, 6(Suppl 1):P13
http://www.jcheminf.com/content/6/S1/P13
© 2014 Furtmann and Bajorath; licensee Chemistry Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
